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Abstract
Bacterial pathogens need to acquire nutrients from the host, but for many nutrients their importance during infection
remain poorly understood. We have investigated the importance of methionine acquisition and synthesis for Streptococcus
pneumoniae growth and virulence using strains with gene deletions affecting a putative methionine ABC transporter
lipoprotein (Sp_0149, metQ) and/or methionine biosynthesis enzymes (Sp_0585 - Sp_0586, metE and metF). Immunoblot
analysis confirmed MetQ was a lipoprotein and present in all S. pneumoniae strains investigated. However, vaccination with
MetQ did not prevent fatal S. pneumoniae infection in mice despite stimulating a strong specific IgG response. Tryptophan
fluorescence spectroscopy and isothermal titration calorimetry demonstrated that MetQ has both a high affinity and
specificity for L-methionine with a KD of ,25 nM, and a DmetQ strain had reduced uptake of C14-methionine. Growth of the
DmetQ/DmetEF strain was greatly impaired in chemically defined medium containing low concentrations of methionine and
in blood but was partially restored by addition of high concentrations of exogenous methionine. Mixed infection models
showed no attenuation of the DmetQ, DmetEF and DmetQ/DmetEF strains in their ability to colonise the mouse
nasopharnyx. In a mouse model of systemic infection although significant infection was established in all mice, there were
reduced spleen bacterial CFU after infection with the DmetQ/DmetEF strain compared to the wild-type strain. These data
demonstrate that Sp_0149 encodes a high affinity methionine ABC transporter lipoprotein and that Sp_0585 – Sp_0586 are
likely to be required for methionine synthesis. Although Sp_0149 and Sp_0585-Sp_0586 make a contribution towards full
virulence, neither was essential for S. pneumoniae survival during infection.
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Introduction
The acquisition of essential nutrients from the host is a
prerequisite for bacterial pathogens to be able to replicate and
so to cause successful infection. Screens for virulence genes as well
as targeted investigation of specific nutrient transporters has
confirmed the importance of nutrient acquisition for the patho-
genesis of infections for many microbial pathogens [1,2,3,4,5,6,7].
One group of nutrients required for bacterial growth are the
amino acids, but there are only limited data on their importance
for bacterial pathogenesis.
Methionine is one of the least abundant amino acids in
physiological fluids (4 mg ml21) [8], and yet is essential for protein
synthesis and is a constituent of S-adenosylmethionine, the major
biological methyl donor required for the biosynthesis of phospho-
lipids and nucleic acids [9]. Two bacterial methionine transport
systems have been described: the Methionine ABC (ATP binding
cassette) Uptake Transporter (MUT) family [10,11] and a
secondary transporter termed BcaP [12]. In Escherichia coli, the
MUT system is encoded by the metD locus and consists of the
MetQ substrate binding protein (SBP), MetL transmembrane
permease and the MetN cytoplasmic ATP-hydrolyzing protein
(ATPase) [11]. E. coli metD mutants are unable to transport D-
methionine or utilize this compound as a source of methionine
[11]. Similar ABC transporters are the primary methionine
transporters for Bacillus subtilis (metNPQ) [10], Streptococcus agalactiae
(metQ1NP) [13] and Streptococcus mutans (atmBDE) [14]. The second
methionine transport system, BcaP was described in Lactococcus
lactis as a branched chain amino acids transporter, but is also
involved in the transport of methionine [12]. Microorganisms and
plants can also synthesize methionine by converting homoserine to
homocysteine through addition of a sulphur group from either
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cysteine (requiring MetABC), sulfide (requiring MetA and CysD)
or methionine using the SAM recycling pathway (MetK, Pfs, and
LuxS) [15,16]. Homocysteine is then methylated by methionine
synthase (MetE) in conjunction with a methylenetetrahydrofolate
reductase (MetF), with the methyl group supplied by 5-methyl
tetrahydrofolate, to form methionine [15,17]. Existing data show
that methionine biosynthetic genes are required for the full
virulence of Brucella melitensis [18], Haemophilus parasuis [19] and
Salmonella enterica [20] and that mutation of the S. agalactiae
methionine regulator MtaR attenuates virulence [8], suggesting
methionine synthesis is essential for survival of many bacteria
during invasive infection.
Streptococcus pneumoniae is a common nasopharyngeal commensal
that is also an important pathogen frequently causing pneumonia,
otitis media, septicaemia and meningitis. A recent investigation of
the role of nine different ABC transporters for S. pneumoniae
virulence identified an ABC transporter encoded by Sp_0148-52
that seemed to be important during pneumonia and septicaemia
[7]. BLAST searches suggested this locus contained genes whose
products have a high degree of identity to MetQNP and AtmBDE
and therefore could be a S. pneumoniae methionine uptake ABC
transporter. In this manuscript we describe in detail the Sp_0148-
52 locus and the role of methionine during S. pneumoniae growth
and virulence. Recombinant Sp_0149 was used to characterise the
potential substrates of this ABC transporter, and deletion mutant
strains of Sp_0149 and metEF were used to investigate role of
methionine acquisition and synthesis during S. pneumoniae growth
and virulence. In addition, as several S. pneumoniae lipoproteins
have been shown to be effective vaccine candidates in animal
models [21,22], we also investigated the potential of recombinant
Sp_0149 as a novel vaccine candidate.
Results
Results of BLAST alignments for Sp_0148-52
The Sp_0148-52 genetic locus was identified during a screen of
ABC transporters for those involved in virulence. In this screen a
mutant containing an insertion within Sp_0149 was attenuated in
virulence in mouse models of pneumonia and sepsis [7]. The
Sp_0148-52 region in the TIGR4 S. pneumoniae strain genome
contains five genes and is 3669 bp in length (Fig. 1 A) [23]. Gene
loci with identical organisation and high levels of identity at the
amino acid level for the corresponding genes are present in S.
agalactiae (SAN_1757-52) [13] and S. mutans (Smu.1942-38) [14]
and contain the metQNP and atmBDE genes respectively that
encode probable methionine ABC transporters. Both Sp_0148
and Sp_0149 possess potential lipoprotein signal sequences,
LAACS (residues 21–25) and LAACG (residues 20–24) respec-
tively, and are annotated in the TIGR4 genome as lipoproteins.
Sp_0148 and Sp_0149 only share 21% identity and 34% similarity
at the amino acid level, so are unlikely to have similar functions or
have arisen by gene duplication. Sp_0148 has been annotated as
an amino acid binding lipoprotein and is highly conserved
amongst sequenced S. pneumoniae strains (98% identity at the
amino acid level) and with proteins encoded by other streptococci
(.49% identity). Sp_0149 is conserved in all the available S.
pneumoniae genomes (.97% identity at the amino acid level) and
has 62% identity at the amino acid level to the lipoprotein
component of the S. mutans methionine transporter atmBCDE [14],
suggesting it may have a similar function. BLAST searches
demonstrate 73% identity at the amino acid level between the
predicted proteins encoded by Sp_0151, atmD and metN (all
predicted ATPases) and 70% for the predicted proteins encoded
by Sp_0152, atmE and metP (all predicted permeases). Hence,
Sp_0149-52 could encode a functional S. pneumoniae methionine
ABC transporter, and therefore we have named Sp_0149 metQ,
Figure 1. Schematic of the Sp_0148-53 and Sp_0584-0587 loci. (A1) Structure of the Sp_0148-53 locus. Each arrow represents one gene, with
the Sp number stated within the arrow and gene annotation and probable function written below. The number of bp between the stop codon of the
upstream gene and the ATG of the downstream gene is given above the arrows in the corresponding gap. (A2) Representation of the structure of the
Sp_0148-53 locus in the DmetQ strain; the erythromycin resistance cassette (eryr) is shaded grey. (B1) Structure of the Sp_0584-0587 locus, with the
Sp number stated and gene annotation when available written below. The number of bp between the stop codon of the upstream gene and the ATG
of the downstream gene is given above the arrows in the corresponding gap. (B2) Structure of the Sp_0584-0587 locus in the DmetEF mutant strain,
showing replacement of metEFgenes with an in-frame copy of cat (shaded grey).
doi:10.1371/journal.pone.0049638.g001
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Sp_0151 metN, and Sp_0152 metP according to the nomenclature
for the genes encoding a putative S. agalactiae methionine ABC
transporter [13].
To investigate whether S. pneumoniae metQNP encode a methi-
onine ABC transporter and the phenotype attributable to loss of its
function, a metQ deletion mutant strain of 0100993 S. pneumoniae
was constructed using a construct made by overlap extension PCR
(Fig. 1A). Complete deletion of Sp_0149-0152 was not done as this
would include deletion of Sp_0150 as well as metQNP. BLAST
results suggested Sp_0150 encodes a protein belonging to the
M20/M40/M45 family of peptidases. Genes encoding similar
proteins are found within the S. mutans (atmC) and S. agalactiae
(pdsM) methionine ABC transporter loci, but the function of the
corresponding proteins is unknown. In addition the Sp_0148
lipoprotein may also utilise the MetN and MetP proteins to form
an ABC transporter, making it difficult to attribute any phenotypes
of an Sp_0149-0152 deletion mutant specifically to a single
function. The correct identity of the mutant was confirmed using
PCR and primers annealing to Sp_0148 or Sp_0150 and the
erythromycin resistance gene eryr (data not shown). Attempts at
complementing the metQ deletion mutant strain using reintegration
of an intact copy of the full length gene were unsuccessful.
However, qPCR demonstrated that expression of the downstream
genes in the operon was not reduced by the DmetQ mutation, with
fold differences (SD) in transcript levels from the DmetQ strain
compared to the wild-type strain of 2.2 (2.3), 1.3 (1.2), and 1.1 (0.2)
for Sp_0150, Sp_0151, and Sp_0152 respectively.
Localisation studies of Sp_0149 lipoprotein
To confirm whether the lipoprotein MetQ is localised to the S.
pneumoniae cell membrane, polyclonal anti-MetQ antibodies were
obtained by intraperitoneal inoculation of recombinant MetQ into
mice. Serum obtained after 4 weeks from inoculated mice
recognised recombinant MetQ protein (Fig. 2A and B), and
immunoblots of whole cell wild-type S. pneumoniae lysates identified
a single band of similar size to the predicted size of MetQ
excluding the lipoprotein signal peptide sequence. The same band
was present when Triton X-114 extracts of membrane bound
proteins were probed with polyclonal anti-MetQ antibodies but
was only present as a weak band in the aqueous fraction (Fig. 2A).
Previous studies have demonstrated that cleavage of the N
terminal lipoprotein signal peptide sequence of lipoproteins
requires lipoprotein signal peptidase (Lsp), and that lipoproteins
in the S. pneumoniae Dlsp mutant are therefore slightly larger than in
the wild type strain [24]. Immunoblotting of whole cell lysates and
aqueous fractions of the Dlsp S. pneumoniae strain with anti-MetQ
serum demonstrated that, as predicted, the band representing
MetQ was slightly larger than in the wild-type strain (Fig. 2A). The
band representing MetQ in the aqueous extracts from the Dlsp
strain was also more prominent that in the wild-type strain,
perhaps suggesting reduced retention of MetQ in the cell
membrane in the absence of the Lsp enzyme. Overall, the
immunoblot results demonstrate that MetQ is mainly associated
with the membrane fraction and is processed by Lsp, confirming
that MetQ is a lipoprotein.
MetQ binds L-methionine with high affinity and is
required for methionine uptake by S. pneumoniae
Potential substrates for the MetQNP ABC transporter were
investigated using fluorescence spectroscopy of recombinant MetQ
(Supplementary Figure 1), a method widely used to investigate
ligand specificity for SBPs due to the large conformational changes
that occurs upon ligand binding [25,26]. We observed an
approximately 30% enhancement of the intrinsic fluorescence of
the protein in the presence of L-methionine (Supplementary Fig. 2)
and we determined a KD of MetQ for L-methionine to be
determined as 26.5861.15 nM (Fig. 3A). We confirmed this tight
binding using isothermal titration calorimetry, which yielded
almost identical binding parameters of 26.5561.28 nM (Fig. 3B),
and also demonstrates 1:1 binding of L-methionine to MetQ.
To investigate the specificity of MetQ for L-methionine, we
examined ligand binding using a range of related ligands. Binding
of D-methionine was around 1000 fold weaker with a KD of
27.460.96 mM, while binding of DL-homocysteine was only
around 250-fold weaker with a KD of 7.060.26 mM (Supplemen-
tary Fig. 3). We also detected weak binding of a-methyl-DL-
methionine with a KD of 30.160.86 mM (Supplementary Fig. 3),
but could not detect any binding for either L-cysteine of glycine
(Supplementary Fig. 2). These data demonstrate that MetQ has a
high affinity and specificity for L-methionine, and confirm that
methionine is the probable major ligand for the S. pneumoniae
MetQNP ABC transporter. To confirm that MetQ is required for
methionine uptake by S. pneumoniae, uptake assays of 14C-labelled
methionine were performed in chemically defined medium with
the wild-type and DmetQ strains [27]. As the mucoid phenotype of
the serotype 3 strain prevents the efficient formation of bacterial
pellets necessary for these assays, the DmetQ mutation was
transferred into a serotype 2 S. pneumoniae strain (D39). In C+Y
medium without added methionine, the DmetQ mutant strain was
unable take up C14-methionine whereas the wild-type strain
demonstrated significant uptake (Fig. 3C). In the presence of
750 mM methionine there was uptake of C14-methionine by the
DmetQ mutant strain suggesting the presence of a lower affinity
methionine transport mechanism (Fig. 3C). These results confirm
that metQNP is a methionine ABC transporter that is required for
methionine uptake by S. pneumoniae when methionine availability is
limited.
Investigation of the lipoprotein MetQ as a vaccine
candidate
Lipoprotein are attached to the external surface of bacterial
membranes and have been shown to be effective vaccines that
protect against S. pneumoniae infection in mouse models [21,22].
Hence, MetQ was investigated as a potential novel vaccine
candidate. PCR (data not shown) and immunoblots demonstrated
that MetQ was present in all of a range of S. pneumoniae strains
from common MLST sequence types for clinically important
capsular serotypes (Fig. 2B). Mice were immunised by three
intraperitoneal injections of 10 ug recombinant MetQ with alum
as the adjuvant separated by 7 or 8 days, which resulted in
significant serum titres of IgG (mainly IgG1) against MetQ that
did not cross-react with the control lipoprotein LivJ (2) (Fig. 4A).
However, when challenged by intraperitoneal inoculation with a
potentially lethal dose of the serotype 2 S. pneumoniae strain D39
there were no differences in the speed of development of fatal
infection and survival between vaccinated and control (given PBS
and the adjuvant alone) mice (Fig. 4B). To investigate whether this
lack of vaccine efficacy despite good anti-MetQ titres was due to
lack of MetQ expression by S. pneumoniae during infection, semi-
quantitative reverse transcriptase PCR (RT-PCR) for metQ
transcripts was performed using S. pneumoniae RNA extracted from
the blood of mice with severe S. pneumoniae septicaemia. As a
positive control RT-PCR was also performed for psaA, which
encodes another lipoprotein that is expressed during infection.
RT-PCR readily identified a product of the right size for metQ, but
at a lower level of expression compared to psaA, suggesting that
relative lack of expression of metQ could be one reason why
vaccination with the MetQ was not protective (Fig. 5B). These
S. pneumoniae metQ and metEF
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data were supported by transcriptome data calculating the relative
abundance of metQ, metE, metF, PsaA and another lipoprotein PiuA
at three anatomical sites during infection (Fig. 5C). The results
show that transcript abundance for metQ, metE and metF were
similar for bacteria found in the nasopharynx, lungs and blood.
Importantly, the amount of metQ transcripts was almost two log10
lower and one log10 lower than the amount of psaA and piuA
transcripts respectively, both of which encode effective lipoprotein
vaccine candidates [28,29,30,31]. These results support the
hypothesis that lack of MetQ adundance during infection could
explain the failure of vaccination with MetQ to provide protection
against systemic disease. Furthermore, when assessed using an
established flow cytometry assay polyclonal anti-MetQ sera did
not significantly improve phagocytosis of other S. pneumoniae strains
by a neutrophil cell line (Fig. 4C).
In vitro phenotypes of the DmetQ, DmetEF and DmetEF/
DmetQ strains
As synthesis of methionine may reduce the effects of loss of
transport of methionine due to the metQ mutation on S. pneumoniae
phenotype, additional mutant strains were constructed containing
deletions of the S. pneumoniae metE and metF [32]. BLAST searches
of S. pneumoniae TIGR4 genome identified the adjacent (and likely
cotranscribed) genes Sp_0585 and Sp_0586 as homologues of the
S. mutans metE and metF genes (47% and 38% identity at the amino
acid level respectively) [14] (Fig. 1B). The genome structure
suggested metE and metF were likely to be contranscribed
independent of the adjacent genes, due to the large gap between
Sp_0584 and Sp_0585, and because Sp_0587 is transcribed in the
opposite direction to Sp_0586 (Fig. 1B). Deletion mutants
replacing metE and metF with a chloramphenicol resistance marker
were made in the wild-type (DmetEF) or in combination with metQ
deletion (DmetEF/DmetQ) S. pneumoniae 0100993 strains (Fig. 1B).
The correct identity of the mutants was confirmed using PCR and
primers annealing to Sp_0584 or Sp_0587 and the chloramphen-
icol resistance gene cat (data not shown).
To investigate the functional importance of methionine
synthesis and uptake for S. pneumoniae, growth of the wild-type,
DmetQ, DmetEF and DmetEF/DmetQ strains were compared in the
complete medium THY and in the semi-defined medium C+Y
with restricted methionine content. In THY there were no
significant differences in growth between the wild-type and DmetQ,
DmetEF and DmetEF/DmetQ strains (Fig. 6A). In C+Y without
added methionine (Fig. 6B), both DmetQ and DmetEF mutant
strains had slightly impaired growth compared to the wild-type
strain, but still reached similar growth levels to the wild-type strain
after 9 hours. However, in C+Y with either no added methionine
or supplemented with only 50 mM of methionine the
double mutant DmetEF/DmetQ had markedly impaired growth
due to reduced generation times (Fig. 6B and C). These
results provide further evidence that MetQ is required for
methionine uptake and indicate that MetEF are necessary for
methionine synthesis. The impaired growth of the DmetEF/DmetQ
strain in C+Y medium was partially restored by addition of
750 mM of methionine (Fig. 6D), suggesting there are additional
weaker affinity secondary transport systems that allow the
DmetEF/DmetQ strain to obtain methionine in the presence of
high concentrations of substrate.
To assess the requirement for methionine for S. pneumoniae
growth in physiologically relevant conditions, replication of these
strains was assessed in freshly obtained human blood. The DmetQ
and DmetEF strains were both significantly impaired in growth in
blood (inoculum size 1.56106 CFU, 10.9 and 7.7 fold increase in
CFU, respectively) compared to the wild type strain (inoculum size
0.56106 CFU, 16.2 fold increase, P,0.001, ANOVA) (Fig. 7A),
although all three strains reached similar total CFU per
ml. Moreover, the DmetEF/DmetQ strain had markedly reduced
growth in blood with only 3.8 fold increase in CFU after 4 hours
and reaching a total CFU of nearly 1 log10 fewer than the
wild-type strain (Fig. 7A). Addition of 1 mM methionine but
Figure 2. Immunoblots of S. pneumoniae using polyclonal anti-MetQ antibodies. (A) Probing of whole cell lysates, lipid and aqueous phases
of Triton X-114 extracts of wild-type, Dlsp, and DmetQ 0100993 strains, and the recombinant MetQ protein (missing the N terminal signal sequence)
with anti-MetQ antibodies. Equal numbers of bacteria were used for each strain, and the approximate sizes of the bands are displayed on the right.
(B) Immunoblots of representative strains for common S. pneumoniae serotypes probed with anti-MetQ antibodies, showing the presence of a similar
band in all strains.
doi:10.1371/journal.pone.0049638.g002
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not leucine (a branched-chain amino acid not linked to the
methionine biosynthetic pathways) largely reversed the growth
defect of the double mutant in blood, without affecting growth of
the wild-type strain (Fig. 7B). These results demonstrate that
absence of methionine uptake and synthesis strongly impairs S.
pneumoniae growth in physiological conditions found during
infection.
In vivo phenotypes of the DmetQ, DmetEF and DmetEF/
DmetQ strains
To investigate the effects of deletion of metQ and/or metEF on
the ability of S. pneumoniae to colonise the nasopharynx, competitive
indices (CIs) for mixed infection with the wild-type and the DmetQ,
or DmetEF or DmetEF/DmetQ strains were determined in a mouse
model of colonisation. None of the mutant strains were reduced in
virulence in the colonisation model when CIs were calculated for
nasal washes obtained 5 days after inoculation (Fig. 8A). Previously
we have shown that a metQ disruption strain was attenuated in
virulence in mouse models of sepsis and pneumonia when
investigated using CIs [7]. To further assess whether the DmetQ
mutation affected the development of infection, groups of 5 CD1
mice each were intranasally inoculated with 107 CFU of the wild-
type or DmetQ strain, and bacterial CFU from the BALF, lungs and
spleens determined after 48 hours (Fig. 8B). There were no
significant differences in the bacterial loads between the wild-type
and DmetQ strains in the BALF, lungs and spleens. Hence although
previously we have shown disruption of metQ strain reduced
virulence in a competitive model of lung infection [7], the DmetQ
strain was still able to cause significant infection when given as a
pure inoculum. The severe growth defect of the double mutant
DmetEF/DmetQ in human blood prompted us to investigate its
growth in a mouse sepsis model. After intraperitoneal inoculation
the number of DmetEF/DmetQ strain CFU recovered from the
blood was approximately two log10 fewer than CFU recovered for
the wild-type strain (P=0.032, Mann Whitney U test) (Fig. 8C).
These data suggested that the inability of the DmetEF/DmetQ strain
to either transport or synthesise methionine has resulted in
decreased but not completely abrogated virulence of this strain in a
mouse sepsis model.
Figure 3. Analysis of L-methionine binding to MetQ. (A) Using tryptophan fluorescence spectroscopy: MetQ (0.05 mM) in 50 mM potassium
phosphate pH 8 was excited at 280 nm at 37uC. Example titration of the MetQ signal change at 342 nm with increasing concentrations of L-
methionine. (B) Binding isotherms for the interaction of MetQ with L-methionine. The top panel display heat changes upon injection of ligand and
the low panel the integrated hears of injection (&) and the best fit (solid line) to a single site binding model. (C) Radioactive uptake of 14C-
methionine expressed as nmol/mg protein over time in minutes by the wild-type (circles, 50 mM of methionine added) and DmetQ (open triangles
50 mM of methionine added, filled triangles 750 mM of methionine added) S. pneumoniae strains.
doi:10.1371/journal.pone.0049638.g003
S. pneumoniae metQ and metEF
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Discussion
In this study, we provide evidence that the S. pneumoniae
Sp_0148-52 locus encodes a methionine uptake ABC transporter
and that Sp_0585 and Sp_0586 encode MetE and MetF required
for methionine biosynthesis. BLAST searches demonstrated that
the Sp_0148-52 and Sp_0585/Sp_0586 encode proteins with high
degrees of similarity to S. mutans AtmBDE and MetEF respectively,
which have been shown to be required for methionine uptake and
synthesis [13,14]. Deletion of the gene encoding the lipoprotein
component Sp_0149 (which we have called metQ) resulted in a
strain that had reduced growth in methionine restricted media and
no detectable uptake of radioactive methionine. Tryptophan
fluorescence spectroscopy confirmed MetQ bound to L-methio-
nine with high affinity as well as D-methionine and homocysteine,
an amino acid that is related to methionine. Deletion of Sp_0585/
Sp_0586 increased the growth defect of the metQ deletion strain in
Figure 4. Investigation of MetQ as a vaccine candidate. (A)
Mouse sera antibody titres to recombinant His-tagged MetQ after
intraperitoneal immunisation with His6-MetQ. Target protein (His6-MetQ
or the negative control SBP His6-LivJ) and IgG class are labelled along
the X axis, and results were obtained using serum from His6-MetQ
vaccinated mice with the exception of the filled triangles which
represent results for serum from control mice (labelled alum). Filled
symbols represent titres for individual mice for the total IgG titre, open
circles for IgG1, and open diamonds for IgG2A titres. Bars represent
median values. (B) Development of fatal disease in mice vaccinated
with His6-MetQ (square symbols) and control (given alum and PBS
alone, diamonds) mice after IP inoculation of 104 CFU of D39 (n = 20).
There were no statistical differences in survival (log rank test). (C)
Phagocytosis of representative S. pneumoniae vaccine serotypes. Key:
bacteria opsonised with: grey bars, HBSS; solid bars, serum from alum
immunised mice; dark grey bars, polyclonal anti-MetQ sera from MetQ
vaccinated mice.
doi:10.1371/journal.pone.0049638.g004
Figure 5. Gene expression of Sp_0149 during infection. (A)
Ethidium stained agarose gel showing equal amplification efficiency for
the primer pairs used for PCR of psaA and metQ when using S.
pneumoniae 0100993 genomic DNA as the template. (B) Ethidium
stained agarose gel of cDNA products generated by RT-PCR after 26 and
30 cycles using S. pneumoniae 0100993 total RNA extracted from the
blood of infected mice and primers for 16S rRNA (internal control), psaA
(positive control) and metQ. (C) Relative mRNA concentrations of
selected genes of S. pneumoniae WCH43 (serotype 4) in various in vivo
niches at 72 h post-intranasal infection of mice. Transcript abundance
for each gene was obtained by microarray analysis, and normalized
against those obtained for the 16S rRNA control. Quantitative fold
differences for each transcript were determined as a ratio of its
abundance to that of the 16S rRNA control. Data are means 6 SEM for
each gene transcript from three replicate challenge experiments.
doi:10.1371/journal.pone.0049638.g005
S. pneumoniae metQ and metEF
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methionine restricted media and in blood, supporting a role for the
products of these genes for methionine synthesis. Genetic
complementation would be helpful to link the metEF and metQ
mutations to these phenotypes but was not possible to achieve, as is
often the case with S. pneumoniae. However the successful
biochemical complementation of the in vitro phenotypes by
exogenous methionine and the lack of impaired transcription of
the rest of the operon in the metQ mutant strongly support that the
observed phenotypes were caused by the mutations. Overall the
data indicate that S. pneumoniae methionine acquisition and
synthesis is largely dependent on the Sp_0148-52 locus and
Sp_0585 and Sp_0586 loci respectively. Unlike the equivalent S.
mutans mutants [14], the S. pneumoniae metQ and metEF mutant
strains were still able to grow in the absence of supplementation
with methionine. This observation and the persisting growth of the
S. pneumoniae DmetQ/metEF double mutant in media containing
high concentrations of methionine suggest that there are
additional mechanisms for S. pneumoniae methionine uptake,
possibly similar to BcaP of L. lactis [12]. One candidate is the
Sp_0481-4 locus which contains an upstream consensus sequence
for the streptococcal methionine regulator MtaR/MetR (data not
shown).
As well as encoding the MetQNP methionine ABC transporter,
the Sp_0148-52 locus also encodes another SBP (Sp_0148)
unrelated to MetQ and a peptidase (Sp_0150). The functions of
these proteins and why their genes are associated with the metQNP
genes are unknown. The peptidase could be required for the
breakdown of extracellular peptides to provide substrates for
MetQNP, but this hypothesis will require further investigation.
Previously it has been suggested that two separate zinc uptake
lipoproteins AdcA and AscAII share the same permease and
ATPase components [33]. Similarly, the Sp_0148 SBP could
associate with MetN and MetP to make an ABC transporter with
separate affinities to the MetQ lipoprotein, perhaps another amino
acid as Sp_0148 has some similarities to proteins annotated as
glutamine SBPs.
Existing vaccines against S. pneumoniae are unable to provide
protection against all strains, prompting the investigation of
surface exposed antigens such as SBPs that are generally highly
conserved between different S. pneumoniae strains as novel vaccine
candidates. Existing data show that several ABC transporters SBPs
are effective vaccines in animal models of S. pneumoniae
[28,30,34,35]. However, vaccination with MetQ did not prevent
fatal systemic infection despite inducing a reasonable antibody
response and the surface location of MetQ. RT-PCR and
transcriptome data suggested that expression of metQ during
actual infection was considerably lower than that of the SBP
vaccine candidates psaA and piuA [36]; this low level of expression
could readily contribute to the lack of protective efficacy of high
titres to the S. pneumoniae MetQ. In addition, unlike IgG raised
against other SBPs [31,34,35], anti-MetQ antibodies did not
promote neutrophil phagocytosis of S. pneumoniae, suggesting these
antibodies are functionally ineffective at promoting immunity.
Several S. pneumoniae ABC transporters have been shown to be
required for full virulence, including those involved in the
acquisition of metals (manganese, zinc, and iron), phosphate,
polyamines, and branched chain amino acids [5,6,7,29,34,35,37].
As methionine is essential for bacterial growth and has restricted
availability in mammalian systems, with a concentration of
4 mg ml21 in physiological fluid, the MetQNP ABC transporter
Figure 6. Growth of the wild-type, DmetQ, DmetEF and DmetEF/DmetQ S. pneumoniae strains in nutrient rich and semi defined media.
Growth measured using OD580 of the wild-type (squares), DmetQ (inverted triangles), DmetEF (triangles) and DmetEF/DmetQ (diamonds) S.
pneumoniae strains grown in THY (A), C+Y with no added methionine (B), C+Y with 50 mM methionine (C), or C+Y with 750 mM methionine (D). Each
data point is the mean log2 OD580 for three samples.
doi:10.1371/journal.pone.0049638.g006
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might also be expected to be important for S. pneumoniae virulence.
Indeed, our previous data using mixed infection experiments with
the wild-type strain and a metQ mutant created by insertional
mutagenesis showed the metQ mutant strain was significantly less
competitive in both pneumonia and sepsis infection models [7].
However, the competitive nature of the mixed infection
model makes it a very stringent test of virulence for
mutant strains, and in this manuscript we have shown that
when given a pure inoculum of the deletion DmetQ or wild-type
strains the progression of infection in mouse model of pneumonia
was very similar. These results are similar to those we have
described for the S. pneumoniae branched chain amino acid ABC
transporter, which also has reduced virulence when competing
against the wild-type strain but could still establish fatal infection
[7]. The double mutant DmetEF/metQ strain was attenuated in
virulence in a sepsis model with lower bacterial CFU than the
wild-type strain, suggesting that methionine synthesis helped to
maintain virulence of the DmetQ strain. However, somewhat
surprisingly the mutant DmetEF/metQ strain was still
able to establish systemic infection in mice, despite its
poor growth in blood in vitro and a circulating methi-
onine level in mammalian blood of 7 to 43 mM, a level
that is associated with a strong growth defect for the this
strain in medium. Similarly, there was no evidence that
deletion of either metQ or metEF individually or in combination
affected colonisation when assessed using highly sensitive compet-
itive infection assays. These results may indicate that local
methionine availability at the site of infection is
relatively high, perhaps due to cell lysis, and adequate
for S. pneumoniae growth even in a strain containing deletions
affecting both high affinity methionine uptake and methionine
biosynthesis. The effect on virulence of some S. pneumo-
niae mutations vary with strain background, and it is
possible that in other strains metQ and metEF deletion
will impair virulence to a greater extent than seen in the
serotype 3 strain used for these studies.
To conclude, we have assessed the role of the MetQNP ABC
transporter and MetEF methionine synthesis enzymes for S.
pneumoniae growth and virulence. The results demonstrate that
MetQNP is required for methionine uptake, and that dual
mutation of metQ and the metEF locus has a profound effect on
growth of S. pneumoniae in methionine restricted conditions.
Figure 7. Growth of the wild-type, DmetQ, DmetEF and DmetEF/DmetQ S. pneumoniae strains in human blood or in human blood
supplemented with amino acids. Data is presented as the mean (SD) fold change in the bacterial CFU per ml at 2 h (clear columns) and at 4 h
(grey columns) in human blood (A) or at 4 h (clear columns) and 6 h (grey columns) in human blood supplemented with amino acids (B). P values for
the differences between the wild-type and the mutant strains at 4 h (A) and between the DmetEF/DmetQ strain with and without added methionine
at 4 h or 6 h (B) were obtained using ANOVA and post hoc tests, *P,0.05, ** p,0.01. Log10 bacterial CFU per ml results for each condition
are given in figures above the corresponding bar in the graphs.
doi:10.1371/journal.pone.0049638.g007
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Methionine uptake and synthesis assisted, but was not essential, for
the development of S. pneumoniae infections. These data provide
more information on the micronutrient requirements of S.
pneumoniae during the development of infection.
Materials and Methods
Ethics statement
All animal experiments were approved by the UCL Biological
Services Ethical Committee and the UK Home Office (Project
Licence PPL70/6510). Experiments were performed according to
UK national guidelines for animal use and care, under UK Home
Office licence.
Bacterial strains, media and growth conditions
The E. coli strain M15 (Qiagen) were used for the cloning of
Sp_0149 lipoprotein gene. Capsular serotypes 2 D39 strain and
capsular serotype 3 S. pneumoniae 0100993 strain were used to
construct S. pneumoniae mutant strains for the in vitro and in vivo
phenotype analysis [1]. A range of S. pneumoniae strains from
common multi-locus sequence typing (MLST) sequence types
(STs) for clinically important capsular serotypes were kind gifts
from Professor Spratt, Imperial College [38]. E. coli was cultured at
37uC using Luria Bertani (LB) broth or agar plates and S.
pneumoniae strains were cultured in the presence of 5% CO2 at
37uC on Columbia agar (Oxoid) supplemented with 5% horse
blood (TCS Biosciences), or in Todd-Hewitt broth supplemented
with 0.5% yeast-extract (Oxoid) or C+Y media [39]. Plasmids and
mutant strains were selected by using appropriate antibiotics
(carbenicillin 100 mg ml21 and kanamycin 25 mg ml21 for E. coli,
0.2 mg ml21 erythromycin for S. pneumoniae). Stocks of S. pneumoniae
were stored as single use 0.5 ml aliquots of THY broth culture
(O.D580 0.3–0.4) at 270uC in 10% glycerol. Growth of S.
pneumoniae strains in broth was monitored by measuring optical
density at 580 nm (OD580). Replication of S. pneumoniae
strains in freshly obtained human blood was deter-
mined by inoculating with 0.5 to 2.06106 CFU ml21
(depending on strain and experiment). After 2, 4, 6 h of
growth at 376C under 5% CO2, serial dilutions were
plated on to blood agar plates to enumerate the CFU.
Fold change was calculated by dividing the results by the
inoculum CFU.
Nucleic acid manipulations, reverse transcriptase PCR
and transcriptome analysis
S. pneumoniae genomic DNA was extracted from bacteria grown
in THY using a modified Wizard genomic DNA kit (Promega) and
RNA using SV total RNA extraction kit (Promega) as previously
Figure 8. Virulence of the DmetQ, DmetEF and DmetEF/DmetQ strains in mouse models of infection. (A) CIs for mixed infections with the
DmetQ, DmetEF and DmetEF/DmetQ and wild-type strains for bacteria recovered from the nasal washes 5 days after colonisation. Each point
represents results for a single mouse, and bars median CIs for the group. (B) Log10 ml
21 bacterial CFU recovered from lungs, BALF and spleens of
mice 24 hours after IN inoculation with 16107 CFU of either the wild-type or DmetQ strain. There were no statistical differences between the strains
for any organ site. (C) Log10 ml
21 bacterial CFU recovered from blood 24 hours after IP inoculation with 36103 CFU of either the wild-type or DmetEF/
DmetQ strain. P=0.0317, Mann Whitney U test.
doi:10.1371/journal.pone.0049638.g008
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described [6]. Total RNA from S. pneumoniae found in mouse blood
was extracted as described by Ogunniyi et al [40]. S. pneumoniae
were harvested from human and mouse blood by brief centrifu-
gation at 825 g at 4uC for 5 minutes. The resulting supernatant
was centrifuged further at 15500 g at 4uC for 5 minutes, and the
bacterial pellet resuspended in 300 ml of pre-warmed (65uC) acid-
phenol (Ambion) and incubated for 5 minutes at 65uC followed by
further addition of 300 ml of pre-warmed NAES buffer and
incubation at 65uC for 5 minutes with intermittent mixing. The
mixture was cooled on ice for 1 minute and centrifuged at 15500 g
for 1 minute, and the aqueous phase was re-extracted twice with
acid-phenol and NAES buffer followed by twice with 300 ml of
chloroform. To this mixture, sodium acetate was added at a final
concentration of 300 mM followed by addition of 2 volumes of
ethanol and RNA was precipitated at 220uC overnight, centri-
fuged at 6000 rpm for 5 minutes and washed in 70% ethanol
before resuspension in 50 ml of nuclease-free water. To the
resulting RNA, recombinant RNasin ribonuclease inhibitor
(Promega N251A) was added to a final concentration of
1 U ml21 and then treated with 0?5 U ml21 RQ1 RNase-free
DNase (Promega M610A) at 37uC for 40 minutes. Aliquots of this
RNA were stored at 270uC until use. An aliquot was used to
check the purity by RT-PCR with and without reverse transcrip-
tase using gene specific primers. qPCR was performed as
previously described [24] using cDNA amplified from
0.4 mg of total RNA using the Applied Biosystems
Geneamp RNA PCR core kit (Applied Biosystems, UK),
and target-specific primers used for Sp_0150, Sp_0151
and Sp_0152 expression (Table 1). For each gene,
crossing point (Cp) values were determined from the
linear region of the amplification plot and normalized
by subtraction of the Cp value for 16S RNA generating a
DCp value. Relative change was determined by subtrac-
tion of the DCp value for the wild-type strain from the
DCp value for the mutant strain (DDCp value), and fold
change calculated using the formula 22DDCp. Transcrip-
tome data for RNA extracted from S. pneumoniae
serotype 4 strain WCH43 recovered from mouse naso-
pharynx, lungs and blood was obtained as described
[41], using whole-genome S. pneumoniae PCR arrays
obtained from the Bacterial Microarray Group at St
George’s Hospital Medical School, London, England
(http://bugs.sghms.ac.uk/). Transcript abundance for each
gene was obtained, and quantitative fold differences
determined as a ratio of a specific gene abundance to
that of the 16S rRNA control.
Restriction digests, ligation of DNA fragments, fractionation of
DNA fragments by electrophoresis, and transformation of E. coli
(by heat shock) were performed according to established protocols
[42]. DNA fragments were purified from electrophoresis gels using
the QIAquick gel extraction kit. RT-PCR was performed using the
Access RT-PCR system (Promega) and gene specific primers
(Table 1). The NCBI website (http://www.ncbi.nlm.nih.gov/blast)
was used to perform BLAST searches and alignments of the
available complete and incomplete bacterial nucleotide and
protein databases. Primers for both PCR and RT-PCR were
designed using sequences displayed by the ARTEMIS software.
Construction of DmetQ, DmetEF and DmetEF/DmetQ S.
pneumoniae mutant strains
Strains, plasmids and primers used for this study are described
in Table 1. Target genes were amplified by PCR from S. pneumoniae
0100993 genomic DNA using primers designed from the TIGR4
genome sequence (http://www.tigr.org) [23]. The DmetQ strain
was constructed by overlap extension PCR [43] using a
transformation fragment in which the Sp_0149/metQ gene had
been replaced by the erythromycin resistance cassette ery. Two
products corresponding to 630 bp 59 (primers Sp0148F and Ery-
Sp0148R) and 672 bp 39 (primers Ery-Sp0150F and Sp0150R) to
metQ were amplified from S. pneumoniae genomic DNA by PCR
carrying 39 and 59 linkers complementary to the 59 and 39 portion
of the ery gene respectively. ery was amplified from pACH74 using
PCR and the primers EryF and EryR [24]. Similarly, For the in-
frame deletion of metEF (Sp_0585-Sp_0586), a construct was
created in which 921 bp of flanking DNA 59 to the Sp_0585 ATG
(primers Sp0583F and Cm-Sp0584R) and 725 bp of flanking
DNA 39 to the Sp_0586 ORF (primers Cm-Sp0587F and
Sp0587R) were amplified by PCR from S. pneumoniae genomic
DNA and fused with the chloramphenicol resistance marker (cat,
amplified from pID701, a suicide vector containing cat gene, with
primers CmF and CmR) by overlap extension PCR. The
constructs were transformed into S. pneumoniae by homologous
recombination and allelic replacement using competence stimu-
lating peptide (CSP-1) (kind gift from D. Morrison) and selection
with antibiotics according to established protocols [1,5]. Deletion
of metQ and/or metEF was confirmed by PCR and sequencing of
the PCR products (performed by Lark Technologies Inc. UK or
UCL sequencing services using the Big DyeTM Terminator
technique and gene specific PCR primers).
Cloning, expression and purification of His6-MetQ
Recombinant MetQ protein was expressed in E. coli and
purified using an N terminal His-tagged QIAexpressionistTM
system. Primers Sp0149.1 and Sp0149.2 amplified a full-length
metQ from the S. pneumoniae D39 strain (excluding the 59 portion
encoding the predicted N-terminal signal peptide), which was then
ligated into the pQE30 expression vector to make the plasmid
pPC138 and transformed into E. coli strain M15. For synthesis
of recombinant proteins, the transformed cells were
grown aerobically in 5 ml of Lennox broth (LB) for 8 h,
and used to inoculate 50 ml LB for overnight aerobic
growth at 376C. This was then used to inoculate 625 ml
of LB at 306C. Cells were allowed to grow aerobically to
an A650 of 0.4–0.6 before production of recombinant
protein was induced with 1 mM isopropyl 1-thio-b-D-
galactopyranoside (IPTG), followed by four hours of
incubation at 306C. Cells were harvested by centrifuga-
tion at 44306 g for 15 min at 46C and resuspended in
buffer A (50 mM potassium phosphate, pH 7.8, 500 mM
NaCl, 10 mM immidazole and 20% glycerol). The cells
were lysed by sonication and cell debris was removed by
centrifugation at 380006 g for 30 min at 46C and the
supernatant containing overexpressed protein was col-
lected. Nickel affinity chromatography was used for the
purification of the hexahistidine tagged protein using
5 ml His-trap column [GE Healthcare]. The soluble
fraction containing the over produced protein was
passed over column pre-equilibrated with buffer A.
Weakly bound contaminants were removed by washing
the column with 20 CV of buffer A containing 40 mM
imidazole and the recombinant protein was eluted with
elution buffer containing 500 mM imidazole. Purifica-
tion products were analysed by SDS-PAGE gel and
shown to contain 99% pure protein of the expected size
for His6-MetQ. Purified protein was dialysed in 50 mM
potassium phosphate pH 7.8 and concentrated using
Vivaspin 5 kDa MWCO concentrators. Protein concen-
tration was determined from the absorbance at 280 nm
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Table 1. Strains, plasmids and primers used in this study. Restriction enzyme sites in primers 59 linkers are underlined.
Name Description (source/reference)
Plasmids
pID701 Shuttle vector for IDM transformation of S. pneumoniae: Cmr (1)
pPC111 pID701 containing an internal portion of Sp_0149 in the XbaI site: Cmr (this study)
DmetQ pGEM-Teasy containing a deletion of Sp_0149: Ampr (this study)
pPC138 pQE30UA carrying full length Sp_0149: Kmr, Ampr (this study)
Strains
0100993 S. pneumoniae capsular serotype 3 clinical isolate (2)
D39 S. pneumoniae capsular serotype 2
TIGR4 S. pneumoniae capsular serotype 4
JSB6B S. pneumoniae capsular serotype 6B (42)
JSB9V S. pneumoniae capsular serotype 9V (42)
JSB14 S. pneumoniae capsular serotype 14 (42)
JSB18C S. pneumoniae capsular serotype 18C
JSB19F S. pneumoniae capsular serotype 19F
JSB23F S. pneumoniae capsular serotype 23F (42)
DmetQ 0100993 containing the Sp_0149 deletion construct: Eryr (this study)
DmetQD39 D39 containing the Sp_0149 deletion made with DmetQ genomic DNA: Eryr (this study)
DmetEF 0100993 containing the Sp_0585and Sp_0586 deletion construct: Cmr (this study)
DmetQ/DmetEF 0100993 containing the metQ and metEF deletion constructs: Eryr and Cmr (this study)
Expression and qPCR Primers
16s.1 GGT GAG TAA CGC GTA GGT AA
16s.2 ACG ATC CGA AAA CCT TCT TC
PsaA.1 CGT TCC GAT TGG GCA AGA C
PsaA.2 GCA CTT GGA ACA CCA TAG
Sp0149.1 GGC TCT TGC AGC TTG CGG








Sp0148F CAC CAA TTG CCC AAA ATC C
Ery-Sp0148R TATT TTAT ATT TTT GTT CAT GAT TCT TTC TCC TTA AAA ATA
Ery-Sp0150 ATT ATT TAA CGG GAG GAA ATA A TAA GAA ACA GGG AGG TGG GAG
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(A280) using a calculated molar extinction coefficients of
45780 cm21 M21 for MetQ. His6-Sp0749 (LivJ) was also
purified using an N terminal His-tagged QIAexpressionistTM
system as described in [7].
Preparation of ligand free His6-MetQ
Binding proteins often co-purify with their cognate
ligands and thus must be made ligand free in order to
check binding with alternate ligands in vitro. Co-
purified ligand was removed from MetQ using guanidi-
nium HCl (GdmHCl) as described previously [44]. The
protein was partially unfolded while bound to the His-
trap column, by including additional wash steps (in
buffer A with 30 mm imidazole) of 40 CV with 2 m
GdmHCl, 4 CV with 1.5 m GdmHCl, 4 CV with 1 m
GdmHCl, 4 CV with 0.5 m GdmHCl, and finally 8 CV
with 0 m GdmHCl. The protein was eluted with elution
buffer as described previously.
Immunoblots and Triton-X-114 extract preparation
S. pneumoniae were grown in THY medium until the OD580
reached 0.6 and the cells were centrifuged, the pellet resuspended
in sterile phosphate buffered saline (PBS) and sonicated. The cell
lysate was centrifuged, and the supernatants used for further
analysis by immunoblotting. Lipid associated proteins were
extracted according to Khandavilli et al [24] using Triton X-114.
Protein samples from Triton X-114 extracts were separated on
SDS-PAGE 10% and 12% resolving gels respectively, blotted onto
nitrocellulose membranes and probed with polyclonal mouse
antisera raised against MetQ (1:2500 dilution) according to
standard protocols [45].
Enzyme Linked Immunosorbent assay (ELISA)
ELISA was performed according to Jomaa et al [31]. Microtitre
ELISA plates were coated with 100 ml of antigen at a concentra-
tion of 5 mg ml21 in TSA buffer and incubated overnight at 4uC.
The plates were washed 5 times with ELISA wash buffer and
soaked in 150 ml of 2% BSA-Tween for 2–4 hours at 37uC and
washed again for 3–4 times with ELISA wash buffer. A 1/1000
dilution of mouse serum was made in BSA-Tween diluent buffer
and added to the first well, and then 2 fold dilutions transferred to
subsequent wells and incubated at 37uC for 4 hours. The wells
were then washed 6 times with ELISA wash buffer and incubated
overnight at 4uC in 100 ml of 1/15000 dilution of goat anti-mouse
IgG conjugated to alkaline phosphate (Sigma) diluted in enzyme
diluent. The ELISA plate was then washed 5 times in ELISA wash
buffer and 100 ml of dinitrophenol (dNP) substrate solution added
to each well and incubated for 1 hour at 37uC (dNP substrate
solution was prepared by adding 1 tablet of dNP (Sigma) in 5 ml of
water). The absorbance was read at 405 nm and antibody titre
was calculated as the lowest dilution giving an OD equal to or
greater than 0.3.
Opsonophagocytosis assays
To assess the effect of anti-metQ antibodies on the interaction of
S. pneumoniae with phagocytes, we measured the proportion of a
neutrophil cell line associated with fluorescent bacteria using a
previously described flow cytometry opsonophagocytosis assay
[31,46]. The complement source used was commercially available
baby rabbit serum (Sigma S7764; rabbit HLA-ABC). S. pneumoniae
strains were fluorescently labelled by incubation with 5, 6-
carboxyfluorescein-succinimidyl ester (FAM-SE; Molecular
Probes, Eugene, Oreg.) solution (10 mg/ml in dimethyl sulfoxide;
Sigma) in 0.1 M sodium bicarbonate buffer for 1 h at 37uC and
then washed six times with Hanks balanced salt solution (HBSS) in
0.2% bovine serum albumin and stored in aliquots at 270uC in
10% glycerol (approximately 109 CFU/ml). The human cell line
HL-60 (promyelocytic leukemia cells; CCL240; American Type
Culture Collection, Manassas, Va.) was used to provide the
effector cells after differentiation into granulocytes by using
previously described protocols. Differentiated HL60 cells were
harvested by centrifugation (1606 g, 8 min, 4uC) and washed
twice with HBSS and once with HBSS in the presence of Ca2+ and
Mg2+. FAM-SE-labelled bacteria (106 CFU) were opsonized with
1/100, 1/40, and 1/10 dilutions of serum in a 96-well plate for
20 min at 37uC with horizontal shaking (170 rpm). Negative
controls were included, using the same volume of HBSS. HL60
cells (105) were added to the opsonized bacteria in the microplate
plate and incubated for 30 min at 37uC with shaking, after which
the bacteria and cells were fixed using 3% paraformaldehyde and
analyzed using flow cytometry. A minimum of 6,000 cells per
sample were analyzed.
14C-methionine uptake assays
Radioactive uptake assays were performed by the rapid
filtration method as previously described [27] with minor
modifications. S. pneumoniae strains were grown in C+Y medium
until the OD620 reached 0.2–0.4. These experiments were
performed using a capsular serotype 2 S. pneumoniae strain (D39)
as the mucoid colonies of the capsular serotype 3 strain prevented
effective pelleting of the bacteria for these assays. Bacteria were
harvested at 13000 g for 20 minutes and resuspended in 50 mM
potassium phosphate buffer (pH 7.2) with 1 mM MgCl2 to an
OD620 between 0.8–1.1. Uptake of methionine was determined in
1 ml assays containing 0.85 ml of bacterial cells and a final
concentration of 50 or 750 mM methionine with 0.125 mCi 14C-
methionine (GE Healthcare, United Kingdom). Samples (150 ml)
containing bacteria, radioactive and non-radioactive substrates
were removed at time intervals (0, 1, 2, and 3 minutes) and
immediately filtered through glass fibre filters (Whatman GF/F),
washed twice with 50 mM potassium phosphate buffer, and then
washed filters placed in scintillation vials in 5 ml of Ready Safe
scintillation cocktail (Beckman Coulter) and radioactivity deter-
mined using a Wallac 1214 RackBeta liquid scintillation counter.
Bichinchoninic acid protein assay (Sigma Aldrich, UK) deter-
mined that an optical density (620 nm) of 1 was equivalent to
0.238 mg protein, and this figure was used to convert the
radioactivity counts to nmol solute per mg protein.
Fluorescence Spectroscopy
Protein fluorescence experiment used a FluoroMax 4
fluorescence spectrometer (Horiba Jobin-Yvon) with
connecting water bath at 376C. Ligand free protein
(MetQ) was used at a concentration of 0.05 mM in 50 mM
potassium phosphate, pH 7.8. Protein was excited at
281 nm with slit widths of 5 nm and emission was
monitored at 352 nm with slit widths of 5 nm. To
examine alternative ligands for MetQ, potential ligands
were added at concentrations up to 5 mM. To determine
the KD for ligand binding, the protein was titrated with
increasing concentrations of the ligand and the corre-
sponding fluorescence change was monitored in time
acquisition mode. The cumulative fluorescence change
was plotted in SigmaPlot and the KD was calculated from
the hyperbolic fit of the binding curve. L-methionine, D-
methionine, DL-Homocysteine, a-Methyl-DL-methio-
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nine, L-Cysteine and Glycine were purchased from
Sigma-Aldrich.
Isothermal Titration Calorimetry
Calorimetry experiment was performed using a VP-
ITC instrument (MicroCal Inc., GE Heath Sciences) by
taking 1.4 ml of ligand free MetQ in the calorimeter cell
and 400 ml of L-methionine ligand in the syringe. The
concentration of ligand in the syringe was typically 10
times that in the cell, whereas the cell concentration was
chosen according to c value of 50, where c=[macromol-
ecule]/(predicted) KD. Experiments were carried out in
50 mM potassium phosphate buffer, pH 7.8, at 376C.
Both cell and syringe solutions were degassed at 356C
for 10 min before use. The titrations were performed as
follows. A single preliminary injection of 3 ml of ligand
solution was followed by 40 injections (6 ml), delivered at
an injection speed of 10 ml s21. Injections were made at
3-min intervals with a stirring speed of 307 rpm. Raw
titration data were integrated and fit to a one-site model
of binding using MicroCal Origin version 7.0.
Animal models of infection models
Infection experiments were performed in age and sex matched
groups of outbred CD1 mice (Charles River Breeders) between 4
to 8 weeks old. For mixed infections, equivalent numbers of
bacteria from stocks of wild-type and mutant S. pneumoniae strains
were mixed and diluted to the appropriate concentration. For the
nasopharyneal colonisation model, 107 CFU of bacteria in 10 ml
were administered by intranasal inoculation under halothane
general anaesthesia, and nasal washes were obtained 5 days post
colonisation. Serial dilutions of the samples were plated onto
Columbia blood agar plates containing optochin (50 mg ml21)
and/or gentamycin (5 mg ml21) to differentiate pneumococcus
from other contaminating streptococci and to enumerate CFU.
The CI was calculated using the formula: ratio of mutant to wild-
type strain recovered from mice divided by the ratio of mutant to
wild-type strain in the inoculum [47]. A CI of less than 1 indicates
the mutant strain is attenuated in virulence compared to the wild-
type strain, and the lower the CI the more attenuated the mutant
strain. Experiments were performed using pure inocula of wild-
type or mutant strains to calculate bacterial CFU in recovered
target organs for each strain at specific time points [47]; for the
systemic model of infection 16103 CFU bacteria in 100 ml were
inoculated by intraperitoneal (IP) injection and spleen homoge-
nates obtained at 24 hours for plating [5,6,24]; and for the
pneumonia model, 56106 CFU bacteria in 40 ml were given by
intranasal (IN) inoculation under halothane general anaesthesia,
and lung homogenates obtained at 48 hours for plating [6,24]. For
the vaccination infections, mice were given by IP injection 100 mg
of MetQ or just PBS mixed with 10% alum on three occasions
separated by 7 to 8 days. Serum was obtained for immunoblots
and antibody titres ELISAs from five mice four weeks after the last
vaccination, and the remaining vaccinated mice challenged by IP
inoculation with 16104 S. pneumoniae D39 strain CFU. Disease
progression was monitored using previously established criteria to
identify mice likely to progress to fatal disease [5].
Statistical analysis
All the in vitro growth curves were performed in triplicates and
represented as means and standard deviations. Results of growth
curves, radioactive uptake and binding assays were analysed using
two-tailed t-tests. Target organ CFU were compared between
strains using the Mann Whitney U test, and the survival of infected
mice using the log rank test.
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